TATVA CHIN PHARM CHEM LTD
Latest filings
- Newspaper publication of Q2 and H1 FY26-27 financial results · Compliance
- Revised Q2 FY27 investor presentation fixes page 12 typo errors · Investor Communications
- Investor presentation: Record quarterly revenue, margin pressure flagged as temporary · Investor Communications
Snapshot
What the business is, and whether it's a good one at a fair price.
Makes specialty chemicals across four operating segments — Phase Transfer Catalysts (PTC), Structure Directing Agents (SDA), Pharma & Specialty Chemical intermediates (PASC) and Electrolyte Salts. In Q1 FY27 the four segments generated segment revenue of ₹428M (PTC), ₹578M (SDA), ₹584M (PASC) and ₹63M (Electrolyte Salts); PTC is positioned as a process-enabling chemistry technology and SDA serves emissions-control applications where Euro 7 implementation is translating into revenue. PASC covers pharma intermediates, with the first molecule entering commercial production in Q1 FY27 and three new molecules expected to add ₹70-80 crore in FY27. The Dahej manufacturing site is essentially saturated and a Dahej-III greenfield unit has been approved with groundbreaking on 20 July 2026, targeting about ₹300 crore peak revenue. The largest input cost is raw materials at 51.9% of revenue, with amines among those whose prices have risen 30-40% on geopolitical factors; most increases are being passed to customers.
Scorecard
Measured from the filed financials, judged against its Specialty Chemicals peers · as of FY26 — not investment advice
Strengths
Nothing stands out in the filed numbers.Concerns
Charts
How has the market priced it — with filings on the timeline?
TATVA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from TATVA CHIN PHARM CHEM LTD's filed financials and exchange disclosures
What does TATVA CHIN PHARM CHEM LTD do?
TATVA CHIN PHARM CHEM LTD is a Chemicals & Petrochemicals company listed on NSE and BSE, trading under the symbol TATVA.
Is TATVA CHIN PHARM CHEM LTD profitable?
Yes. Over the trailing twelve months TATVA CHIN PHARM CHEM LTD reported a net profit of ₹51 Cr on revenue of ₹556 Cr.
Does TATVA CHIN PHARM CHEM LTD pay a dividend?
Yes. The dividend yield is 0.06% at the current price. It paid out 6% of its profit as dividend in FY26.
Is TATVA CHIN PHARM CHEM LTD debt-free?
No. It reported borrowings of ₹120 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹115 Cr after cash. Debt stands at 0.15× equity. That is lower than 54% of its 99 Specialty Chemicals peers.
Is TATVA CHIN PHARM CHEM LTD expensive compared with its peers?
On trailing P/E, TATVA CHIN PHARM CHEM LTD ranks 87 of 99 in Specialty Chemicals — cheaper than 12% of them, against an industry median of 23.0×. This is a position, not a valuation judgement.
How much does the TATVA CHIN PHARM CHEM LTD share price move in a day?
On a typical session TATVA CHIN PHARM CHEM LTD moves 1.84% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
Where can I track TATVA CHIN PHARM CHEM LTD's announcements?
Every NSE and BSE filing by TATVA CHIN PHARM CHEM LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.